Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 515

1.

Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.

Goforth R, Salem AK, Zhu X, Miles S, Zhang XQ, Lee JH, Sandler AD.

Cancer Immunol Immunother. 2009 Apr;58(4):517-30. doi: 10.1007/s00262-008-0574-6. Epub 2008 Aug 22.

PMID:
18719913
2.

Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity.

Heit A, Schmitz F, Haas T, Busch DH, Wagner H.

Eur J Immunol. 2007 Aug;37(8):2063-74.

3.

An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.

Jacobs C, Duewell P, Heckelsmiller K, Wei J, Bauernfeind F, Ellermeier J, Kisser U, Bauer CA, Dauer M, Eigler A, Maraskovsky E, Endres S, Schnurr M.

Int J Cancer. 2011 Feb 15;128(4):897-907. doi: 10.1002/ijc.25399.

4.

Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles.

Rosalia RA, Silva AL, Camps M, Allam A, Jiskoot W, van der Burg SH, Ossendorp F, Oostendorp J.

Cancer Immunol Immunother. 2013 Jul;62(7):1161-73. doi: 10.1007/s00262-013-1411-0. Epub 2013 Apr 24.

PMID:
23613147
6.

CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.

Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, de Gruijl T, Löwik C, Oostendorp J, van der Burg SH, Ossendorp F.

Biomaterials. 2015 Feb;40:88-97. doi: 10.1016/j.biomaterials.2014.10.053. Epub 2014 Nov 26.

PMID:
25465442
7.
8.

Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.

Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J, Lavasanifar A.

Vaccine. 2008 Sep 15;26(39):5046-57. doi: 10.1016/j.vaccine.2008.07.035. Epub 2008 Aug 3.

PMID:
18680779
9.

Relationship of vaccine efficacy to the kinetics of DC and T-cell responses induced by PLG-based cancer vaccines.

Ali OA, Doherty E, Mooney DJ, Emerich D.

Biomatter. 2011 Jul-Sep;1(1):66-75. doi: 10.4161/biom.1.1.16277.

10.

Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.

Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.

Eur J Immunol. 2009 Oct;39(10):2725-36. doi: 10.1002/eji.200939543.

11.

Microsphere priming facilitates induction of potent therapeutic T-cell immune responses against autochthonous liver cancers.

Brinkhoff B, Ostroumov D, Heemcke J, Woller N, Gürlevik E, Manns MP, Longerich T, Zender L, Harty JT, Kubicka S, Kühnel F, Wirth TC.

Eur J Immunol. 2014 Apr;44(4):1213-24. doi: 10.1002/eji.201343794. Epub 2014 Jan 16.

13.

Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.

Aravindaram K, Wang PH, Yin SY, Yang NS.

Gene Ther. 2014 May;21(5):457-67. doi: 10.1038/gt.2014.12. Epub 2014 Feb 27.

PMID:
24572790
14.

Regulatory T-cell depletion synergizes with gp96-mediated cellular responses and antitumor activity.

Yan X, Zhang X, Wang Y, Li X, Wang S, Zhao B, Li Y, Ju Y, Chen L, Liu W, Meng S.

Cancer Immunol Immunother. 2011 Dec;60(12):1763-74. doi: 10.1007/s00262-011-1076-5. Epub 2011 Jul 26.

PMID:
21789592
15.

Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics.

Jarnicki AG, Conroy H, Brereton C, Donnelly G, Toomey D, Walsh K, Sweeney C, Leavy O, Fletcher J, Lavelle EC, Dunne P, Mills KH.

J Immunol. 2008 Mar 15;180(6):3797-806.

16.

Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.

Gehrmann U, Hiltbrunner S, Georgoudaki AM, Karlsson MC, Näslund TI, Gabrielsson S.

Cancer Res. 2013 Jul 1;73(13):3865-76. doi: 10.1158/0008-5472.CAN-12-3918. Epub 2013 May 8.

17.

Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.

Chaput N, Schartz NE, André F, Taïeb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M, Adema G, Adams M, Ferrantini M, Carpentier AF, Escudier B, Tursz T, Angevin E, Zitvogel L.

J Immunol. 2004 Feb 15;172(4):2137-46.

18.

Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery.

Zhang Z, Tongchusak S, Mizukami Y, Kang YJ, Ioji T, Touma M, Reinhold B, Keskin DB, Reinherz EL, Sasada T.

Biomaterials. 2011 May;32(14):3666-78. doi: 10.1016/j.biomaterials.2011.01.067. Epub 2011 Feb 23.

PMID:
21345488
19.

Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity.

Hokey DA, Larregina AT, Erdos G, Watkins SC, Falo LD Jr.

Cancer Res. 2005 Nov 1;65(21):10059-67.

20.

Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.

Guo Y, Wang D, Song Q, Wu T, Zhuang X, Bao Y, Kong M, Qi Y, Tan S, Zhang Z.

ACS Nano. 2015 Jul 28;9(7):6918-33. doi: 10.1021/acsnano.5b01042. Epub 2015 Jul 14.

PMID:
26153897

Supplemental Content

Support Center